© FT montage: Ian Bott/Dreamstime

How science is getting closer to a world without animal testing

New technology involving miniature human organs built in a lab is a step towards better treatments and ending a contentious practice

Alex Blyth thought his company had a genius strategy to reinvent cancer treatment. By examining the immunity of the lucky few who had no family history of the disease, Lift Biosciences discovered a potential treatment to destroy tumours for everyone else. Then the cell therapy hit a snag: it did not work when tested on mice.

The bad news came just as Blyth was about to sign a £20mn-plus fundraising round for his Cambridge-based biotech. Investors were shaken by the poor data from the pre-clinical study and, suddenly, he could only raise £5mn, at a lower valuation.

But Lift’s chief scientist Oxana Polyakova turned to a novel technology that replicates a miniature human tumour in a dish: a tumoroid. When used on the tumoroid the drug “totally trashed” the cancer, Blyth says, to the point where a patient would have been in complete remission.

“It showed we had something that really worked. Investors were thrilled: they had just come in at the lower round,” he says. “I wasn’t so thrilled.”

FT

Blockierte Fortpflanzung: Mit Gentechnik gegen unerwünschte Insekten

Bakterien, die sich von Methanol ernähren und nachhaltige Chemikalien produzieren.   (Illustration: Sean Kilian)

Bakterien für klimaneutrale Chemikalien der Zukunft

Grün, blau und rot eingefärbte Blasentumor-Organoide.

Mit einem Tumor-Avatar gezielter gegen Blasenkrebs

Wie wird die Sicherheit von Gesundheitsdaten gewährleistet?

Zelle mit komplett künstlich hergestellterDNA in Betrieb genommen

Wird die isolierende Myelinschicht einer Nervenfaser fälschlicherweise durch das Immunsystem beschädigt, können Nervenzellen ihre Signale nicht weiterleiten.

Die Ursache des Guillain-Barré-Syndroms aufgeklärt